Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Meta-Analysis Links Diabetes to Increased Blood Cancer Risk

By BiotechDaily International staff writers
Posted on 21 Jun 2012
ADVERTISEMENT
SARTORIUS AG
According to a new, worldwide meta-analysis, patients with type 2 diabetes have a significantly increased risk of developing certain types of blood cancers.

A collaborative study led by researchers at The Miriam Hospital (Providence, RI, USA) analyzed 26 (13 case-control and 13 cohort) published observational studies that had evaluated the association between diabetes mellitus type 2 and the incidence of lymphoma, leukemia, and myeloma. The meta-analysis included more than 17,000 cases of type 2 diabetes and blood cancer worldwide. The researchers concluded that patients with type 2 diabetes have about 20% increased risk of developing leukemia, myeloma, and non-Hodgkin lymphoma, as well as a subtype of non-Hodgkin lymphoma known as peripheral T-cell lymphoma. They did not find any associations with Hodgkin lymphoma. The findings suggest type 2 diabetes could be associated with approximately 5% of all incidents of leukemia, myeloma, and non-Hodgkin lymphoma.

The researchers also found that the risk of lymphoma, leukemia, and myeloma appears to differ depending on the geographic region of the original report. For example, the risk of non-Hodgkin lymphoma was higher in Asia and Europe, while there was an increased leukemia risk in the United States and Asia.

“When you consider that [millions of people have type 2 diabetes and that millions more are still likely to develop it], a 20% increased risk of blood cancer is quite significant,” noted lead author Jorge Castillo, MD, a hematologist-oncologist with The Miriam Hospital. He added, “It’s important to remember that type 2 diabetes can, to some degree, be prevented and controlled through lifestyle modification, such as diet and exercise; so by preventing the onset of type 2 diabetes, we could also prevent blood cancer.” Dr. Castillo and colleagues suggested that, in addition to studying antidiabetic therapy, future research should focus particularly on evaluating roles of behavioral factors such as obesity, physical activity, dietary habits, and smoking, which have been linked to both diabetes and cancer.

The findings, published online May 24, 2012, in the American Society of Hematology journal Blood, add to the growing evidence base linking diabetes and certain types of cancer.

Related Links:

The Miriam Hospital



Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.